p-EGFR Antibody (1H9): sc-57543

p-EGFR Antibody (1H9) is a mouse monoclonal IgG1 antibody raised against synthetic phosphopeptide corresponding to amino acid residues surrounding Serine 1047 of EGFR of human origin. p-EGFR monoclonal antibody (1H9) detects p-EGFR in mouse, rat, human, and canine samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). Anti-p-EGFR antibody (1H9) recognizes phosphorylated forms of EGFR, which is crucial for understanding its role in cell signaling and growth regulation. EGFR is primarily located on the cell surface, where EGFR functions as a receptor for epidermal growth factors, mediating various cellular processes including proliferation, differentiation, and survival. EGFR′s location enables initiation of signaling cascades upon ligand binding, leading to autophosphorylation at specific tyrosine residues, such as Tyr 1092 and Tyr 1173. These phosphorylation events are essential for recruiting downstream signaling proteins, such as GRB2, and activating pathways like Ras, which are pivotal in cancer progression and other diseases. p-EGFR monoclonal antibody (1H9) enables researchers to gain insights into the activation status of EGFR and implications in various biological contexts, making p-EGFR (1H9) antibody a valuable tool for studies in cancer research and therapeutic development.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-EGFR Antibody (1H9) References:

1. Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas.  |  Hiraishi, Y., et al. 2006. Pathol Oncol Res. 12: 87-91. PMID: 16799709
2. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.  |  McMillen, E., et al. 2010. Exp Lung Res. 36: 531-7. PMID: 20939760
3. EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confers independent prognostic impact.  |  Li, CF., et al. 2012. Ann Surg Oncol. 19: 443-54. PMID: 21761100
4. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.  |  Wang, F., et al. 2012. J Exp Clin Cancer Res. 31: 65. PMID: 22901364
5. EGFR and phosphorylated EGFR in relation to HPV and clinical outcome in tonsillar cancer.  |  Romanitan, M., et al. 2013. Anticancer Res. 33: 1575-83. PMID: 23564800
6. Expression of P-EGFR and P-Akt protein in esophageal squamous cell carcinoma and its prognosis.  |  Shan, ZZ., et al. 2017. Oncol Lett. 14: 2859-2863. PMID: 28927043
7. miR-22-3p enhances the intrinsic regenerative abilities of primary sensory neurons via the CBL/p-EGFR/p-STAT3/GAP43/p-GAP43 axis.  |  Li, B., et al. 2020. J Cell Physiol. 235: 4605-4617. PMID: 31663116
8. Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis.  |  Chen, X., et al. 2021. Front Oncol. 11: 697369. PMID: 34490092
9. Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis.  |  Hong, X., et al. 2022. Medicine (Baltimore). 101: e28507. PMID: 35060503
10. GLUT1 promotes cell proliferation via binds and stabilizes phosphorylated EGFR in lung adenocarcinoma.  |  Zhou, Z., et al. 2024. Cell Commun Signal. 22: 303. PMID: 38831321

The preferred EGFR antibody is EGFR Antibody (528): sc-120.